Skip to main
HCAT
HCAT logo

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc. reported a revenue of $79.6 million, reflecting a year-over-year increase of 6% and aligning closely with expectations, highlighting the firm's ongoing focus on scaling higher-margin, recurring technology revenue. The company is poised to add approximately 40 net new platform clients in FY25, significantly up from 21 in the previous year, driven by successful cross-selling strategies to an extensive base of over 900 application clients. Additionally, Health Catalyst has modestly revised its EBITDA guidance upward by $2 million, suggesting confidence in achieving operational efficiencies and a favorable market position as it anticipates strong business signings in the upcoming quarters.

Bears say

Health Catalyst Inc. is facing significant challenges that contribute to a negative outlook for its stock. The company’s EBITDA guidance of approximately $4 million for 2025, which is down 55% from consensus expectations of $8.8 million, indicates a concerning inability to meet performance targets amid a slower-than-anticipated ramp-up in the second half of 2025. Additionally, revenue guidance of $79 million for the first quarter of 2025 falls short of analysts' expectations of $82 million, along with complications arising from shifts in business mix and ongoing challenges related to the adoption of new technology platforms.

HCAT has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Buy based on their latest research and market trends.

According to 20 analysts, HCAT has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.